ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$14.79 USD
-0.06 (-0.40%)
Updated May 17, 2024 04:00 PM ET
After-Market: $14.78 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACAD 14.79 -0.06(-0.40%)
Will ACAD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Other News for ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACAD July 19th Options Begin Trading
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Cantor picks 14 undervalued biotech stocks worth a second look
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)